Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LymeShield
- Development stage
- Unknown
- Lead developer
- US Biologic
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
LymeShield is an oral vaccine developed by US Biologic to prevent the transmission of Lyme disease by targeting the primary wildlife reservoir, specifically white-footed mice (*Peromyscus leucopus*). The vaccine utilizes the OrisBio platform, which employs *Bacillus subtilis* spores to express the Outer Surface Protein A (OspA) of *Borrelia burgdorferi*. When consumed by mice via spray-coated food pellets, the vaccine induces the production of anti-OspA antibodies. These antibodies are then ingested by ticks during a blood meal, where they neutralize the bacteria within the tick's midgut, thereby breaking the transmission cycle to humans. The vaccine received USDA conditional licensure in 2023.
- Brand names
- LymeShield
- Other names
- Borrelia Burgdorferi BacterinOral Lyme Disease Vaccine
02
Targets
OspA (Outer surface protein A)
Beyond the preview
Go deeper on LymeShield.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LymeShield.